These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15536692)

  • 21. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels.
    Wilson R; McKillop JH; Pearson DW; Cuthbert GF; Thomson JA
    J Nucl Med; 1985 Sep; 26(9):1024-8. PubMed ID: 2863338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Current methods of radionuclide diagnosis and radiodine therapy in toxic goiter].
    Purizhanskiĭ II; Lyzhina VD; Romanenko AM; Lisenkov PI
    Med Radiol (Mosk); 1980 Dec; 25(12):53-7. PubMed ID: 6894013
    [No Abstract]   [Full Text] [Related]  

  • 23. Somatostatin receptor scintigraphy using (99m)Tc-EDDA/HYNIC-TOC in graves' disease.
    Gabriel M; Decristoforo C; Moncayo R
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1267. PubMed ID: 12418470
    [No Abstract]   [Full Text] [Related]  

  • 24. Graves' disease. Initial presentation with exophthalmos and solitary hot nodule.
    Vento JA; Slavin JD; Reardon GE; Spencer RP
    Clin Nucl Med; 1986 Jun; 11(6):404-6. PubMed ID: 3013482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroid vascularization by color doppler ultrasonography in Graves' disease. Changes related to different phases and to the long-term outcome of the disease.
    Baldini M; Castagnone D; Rivolta R; Meroni L; Pappalettera M; Cantalamessa L
    Thyroid; 1997 Dec; 7(6):823-8. PubMed ID: 9459623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of integrity of thyroid morphology and function in children born to mothers with inadequately treated Graves' disease.
    Kempers MJ; van Trotsenburg AS; van Rijn RR; Smets AM; Smit BJ; de Vijlder JJ; Vulsma T
    J Clin Endocrinol Metab; 2007 Aug; 92(8):2984-91. PubMed ID: 17504907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Measurements of the thyroid scans of normal persons and diffuse toxic goiter in Taiwan.
    Yang KT; Lee YJ; Wu CC
    Taiwan Yi Xue Hui Za Zhi; 1986 May; 85(5):479-82. PubMed ID: 3463655
    [No Abstract]   [Full Text] [Related]  

  • 28. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
    Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic trinity: Graves' disease on F-18 FDG PET.
    Chen YK; Wang YF; Chiu JS
    Clin Nucl Med; 2007 Oct; 32(10):816-7. PubMed ID: 17885368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [F-qi-FDG PET of the thyroid gland in Graves' disease].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxic Graves' disease with thyroid hemiagenesis: diagnosis using thyroid-stimulating immunoglobulin measurements.
    Shechner C; Kraiem Z; Zuckerman E; Dickstein G
    Thyroid; 1992; 2(2):133-5. PubMed ID: 1356055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [In vivo determination of thyroid iodine content in functional autonomy].
    Leisner B
    Acta Med Austriaca; 1990; 17 Suppl 1():33-5. PubMed ID: 2117838
    [No Abstract]   [Full Text] [Related]  

  • 33. [The place of nuclear medicine methods in thyroid gland diagnosis].
    Becker W; Reiners C; Börner W
    Schweiz Med Wochenschr; 1984 Nov; 114(47):1701-3. PubMed ID: 6549080
    [No Abstract]   [Full Text] [Related]  

  • 34. Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease.
    Vitti P
    Eur J Endocrinol; 2000 Jan; 142(1):22-4. PubMed ID: 10633216
    [No Abstract]   [Full Text] [Related]  

  • 35. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.
    Ota H; Amino N; Morita S; Kobayashi K; Kubota S; Fukata S; Kamiyama N; Miyauchi A
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):41-5. PubMed ID: 17437515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diffusion-weighed MR of the thyroid gland in Graves' disease: assessment of disease activity and prediction of outcome.
    Abdel Razek AA; Sadek AG; Gaballa G
    Acad Radiol; 2010 Jun; 17(6):779-83. PubMed ID: 20350826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Change of 99m technetium-pertechnetate uptake by the thyroid under suppression (TcTus) induced by optimization of iodine supply in Germany].
    Reinhardt MJ; Trupkovic T; Schumacher T; Krause TM; Oexle C; Moser E
    Nuklearmedizin; 1998; 37(6):202-7. PubMed ID: 9770714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid uptake of Technegas during V/Q scintigraphy in Graves disease.
    Tan AE; Pua U
    Am J Med; 2010 May; 123(5):e3-4. PubMed ID: 20399306
    [No Abstract]   [Full Text] [Related]  

  • 39. Thyroid trapping technetium-99m during in vivo labelling of RBCs.
    Van Nostrand D; Smallridge RC
    J Nucl Med; 1982 Dec; 23(12):1146-7. PubMed ID: 6897263
    [No Abstract]   [Full Text] [Related]  

  • 40. Is thyroid scintigraphy necessary before I-131 therapy for hyperthyroidism? Concise communication.
    Ripley SD; Freitas JE; Nagle CE
    J Nucl Med; 1984 Jun; 25(6):664-7. PubMed ID: 6327946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.